Date: 2013-06-25
Type of information: Grant
Company: F2G (UK)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: € 6.1 million
Funding type: grant
Planned used: The NOFUN project brings together five partners to accelerate the development of a number of F2G’s broad spectrum antifungal agents. Participants in the NOFUN Project are F2G Ltd (UK), The University of Manchester (UK), Pharmacelsus GmbH (Germany), OncoTargeting AB (Sweden) and Universitat i Rovira Virgili (Spain). This project aims to develop novel agents with completely new ways of acting in order to combat the increasing tide of drug resistant fungal infections. NOFUN will use F2G’s discovery assets and the University’s fungal genomics platforms in addition to the drug development and characterisation expertise of the other partners. The premise of the NOFUN project is to expand upon work already undertaken by members of the consortium to rapidly progress a number of novel antifungal agents. It aims to develop new chemical classes of antifungal drugs with novel mechanisms of action that will address unmet medical need and address the problems of intrinsic and acquired resistance blighting existing therapies. Target Product Profiles against resistant fungi have been developed: broad spectrum agent with activity against azole resistant Candida and Apsergillus ; narrow spectrum agent against azole resistant Candida/Aspergillus ; narrow spectrum agent against intrinsically resistant moulds ; broad spectrum agent to treat superficial and ocular infections.
Others: * On June 25, 2014, F2G Ltd, a privately-held antifungal drug discovery and development company and The University of Manchester, announced the commencement of a 6.1 million euro EU -funded project to discover and develop novel antifungal drugs to treat serious, life-threatening fungal infections. The NOFUN project is a collaborative project under the 7th Framework Program of the European Commission.
Therapeutic area: Infectious diseases
